Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
|
|
- Godwin Fields
- 6 years ago
- Views:
Transcription
1 Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
2 Molecular testing has become the primary tool for precision medicine. NeoGenomics is a full-service cancer diagnostic laboratory committed to helping the cancer community incorporate informative, effective, and innovative tests into the care of their patients. With over 155 molecular assays in-house, we provide one of the largest oncology-focused molecular test menus available along with top-quality consultation and laboratory services in cytogenetics, FISH, flow cytometry, and IHC. NeoGenomics has developed a unique expertise in analysis and reporting of cancer biomarkers. By having one of the fastest development cycles in the industry, we are also responsive to opportunities to improve service and patient care. We rapidly bring our clients state-of-the-art tests for newly reported, significant genetic indicators for disease diagnosis and classification, assessing prognosis, and selecting therapy. Our oncology and pathology clients always have the flexibility to customize their orders to their patient s specific needs. Highlights of Our Molecular Program Include: One of the most comprehensive oncology-focused menus of single-gene and multi-parameter tumor profiles available Full range of molecular diagnostic technologies including next-gen sequencing, quantitative PCR, gold-standard Sanger sequencing, fragment analysis, and SNP microarray Extensive cell-free DNA/RNA liquid biopsy testing capabilities useful for diagnostic screening, monitoring and detecting minimal residual disease All complementary testing methods including morphology, cytogenetics, FISH, flow cytometry, and IHC are available in-house, which maximizes yield from small specimens and minimizes TAT Growing hereditary cancer testing menu using leading-edge platforms Pharma Services supporting academic institutions, pharmaceutical companies, and the biotechnology industry Testing enhancements to improve detection of low-level abnormalities in select assays through plasma analysis and high-sensitivity sequencing Molecular Testing Capabilities Somatic Germline Early Detection/ Prediction 2 NeoGenomics Laboratories
3 Solid Tumor Tests All Tumors Microsatellite Instability Analysis (MSI) NeoARRAY SNP/Cytogenetic Profile NeoLAB Solid Tumor Monitor NeoTYPE Discovery Profile for Solid Tumors NeoTYPE Precision Profile for Solid Tumors Tumor Mutation Burden Universal Expression/Fusion Profile Brain ATRX viii Analysis IDH1/IDH2 MGMT Promoter Methylation NeoTYPE Brain Tumor Profile TERT Promoter Breast NeoTYPE Breast Tumor Profile Cervical RAF NeoTYPE Cervical Tumor Profile NOTCH1 Colorectal Exon 4 Microsatellite Instability Analysis (MSI) MLH1 Promoter Methylation NeoTYPE Colorectal Tumor Profile NeoTYPE GI Predictive Profile NOTCH1 Exon 4 RAS/RAF Panel Esophageal NeoTYPE Esophageal Tumor Profile NeoTYPE GI Predictive Profile Gastric NeoTYPE Gastric Tumor Profile NeoTYPE GI Predictive Profile GIST NeoTYPE GIST Profile Lung ALK MET MET Exon 14 Deletion Analysis NeoLAB T790M - NeoTYPE Lung Tumor Profile NGS ALK, NTRK, RET, ROS1 Fusion Profile NGS ALK, RET, ROS1 Fusion Profile Oncomine Dx Target Test Melanoma NeoARRAY SNP/Cytogenetic Profile NeoTYPE Melanoma Profile TERT Promoter Ovarian NeoTYPE Ovarian Tumor Profile TP53 Soft Tissue NeoTYPE Liposarcoma Fusion Profile NeoTYPE Soft Tissue Tumor Profile NGS Comprehensive Sarcoma Fusion Profile NGS Ewing Sarcoma Fusion Profile NGS Non-Ewing Sarcoma Fusion Profile NGS Pediatric Sarcoma Fusion Profile NGS Rhabdomyosarcoma Fusion Profile Prostate Androgen Receptor Mutation Analysis HSD3B1 Genotyping NeoLAB Prostate - Thyroid HRAS NeoTYPE Thyroid Profile NGS ALK, NTRK, RET, ROS1 Fusion Profile NGS ALK, RET, ROS1 Fusion Profile NGS Thyroid Fusion Profile TERT Promoter Other Tumors HPV DNA Tissue Testing NeoTYPE Head & Neck Tumor Profile NeoTYPE Liver/Biliary Tumor Profile NeoTYPE Other Solid Tumor Profile NeoTYPE Pancreas Tumor Profile NeoGenomics Laboratories 3
4 Hematologic Diseases Leukemias AML ASXL1 CEBPA DNMT3A ETV6-RUNX1 t(12;21) FLT3 IDH1 IDH2 Inv(16) CBFB-MYH11 NeoLAB AML Profile - NeoLAB FLT3 Mutation Analysis - NeoLAB IDH2 Mutation Analysis - NeoLAB Inv(16), CBFB-MYH11 Translocation - NeoLAB (c-) Mutation Analysis - Liquid Biopsy NeoLAB Mutation Analysis - NeoLAB NPM1 Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB PML-RARA Translocation, t(16;17) - Liquid Biopsy NeoTYPE AML Favorable Risk Profile NeoTYPE AML Prognostic Profile NPM1 NPM1 MRD Analysis PML-RARA t(15;17) RUNX1 RUNX1-RUNX1T1 t(8;21) TP53 APL PML-RARA t(15;17) ALL ABL1 Kinase Domain Mutation B-Cell Gene Rearrangement BCR-ABL1 t(9;22) ETV6-RUNX1 t(12;21) IgH Clonality/MRD by NGS T-Cell Beta Gene Rearrangement T-Cell Gamma Gene Rearrangement TPMT Genotyping CLL BTK Inhibitor Acquired Resistance Panel BTK IgVH NeoLAB BTK Inhibitor Acquired Resistance Panel - NeoTYPE CLL Prognostic Profile NOTCH1 PLC-Gamma-2 SF3B1 JMML NeoLAB Mutation Analysis - NeoTYPE JMML Profile PTPN11 Other Leukemias Hairy Cell: LGLL: STAT3, T-Cell Lymphomas B-Cell Gene Rearrangement BCL1 t(11;14) BCL2 t(14;18) BTK Inhibitor Acquired Resistance Panel BTK Inhibitor Primary Susceptibility Panel EZH2 IgH Clonality/MRD by NGS MYD88 NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile NeoTYPE Lymphoma Profile RHOA Mutation Analysis T-Cell Beta Gene Rearrangement T-Cell Gamma Gene Rearrangement TET2 Myelodysplastic Syndromes ASXL1 ETV6 EZH2 NeoARRAY SNP/Cytogenetic Profile NeoLAB Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB MDS/CMML Profile - NeoTYPE MDS/CMML Profile PPM1D RUNX1 SF3B1 TET2 TP53 Myeloproliferative Neoplasms BCR-ABL1 t(9;22) BCR-ABL p230 CALR JAK2 Exon JAK2 V617F MPL MPN Extended Reflex Panel MPN Standard Reflex Panel NeoLAB Mutation Analysis - NeoTYPE MPN Profile CML ABL1 BCR-ABL1 t(9;22) CSF3R for acml Plasma Cell Myeloma B-Cell Gene Rearrangement Transplant Chimerism/DNA Fingerprinting 4 NeoGenomics Laboratories
5 Hereditary Cancer Tests BRCA1 Mutation & Del/Dup Analysis BRCA1/2 Mutation & Del/Dup Analysis BRCA2 Mutation & Del/Dup Analysis T790M Germline Mutation Analysis Hereditary Cancer Comprehensive Panel Hereditary Cancer Susceptibility for Pediatrics Hereditary DNA Repair Panel for Prostate Cancer HOXB13 Genotyping Inherited Bone Marrow Failure Panel Lynch Syndrome NeoLAB Tests NeoLAB AML Profile - NeoLAB BTK Inhibitor Acquired Resistance Panel - NeoLAB T790M - NeoLAB FLT3 Mutation Analysis - NeoLAB IDH1 Mutation Analysis - NeoLAB IDH2 Mutation Analysis - NeoLAB inv(16), CBFB-MYH11 Translocation - NeoLAB (c-) Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB MDS/CMML Profile - NeoLAB Myeloid Disorders Profile - NeoLAB NPM1 Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB PML-RARA Translocation, t(15;17) - NeoLAB Prostate - NeoLAB RUNX1-RUNX1T1 (AML-ETO) - NeoLAB Solid Tumor Monitor - NeoGenomics Laboratories 5
6 Test Menu Single Gene Tests ABL1 Kinase Domain ALK Androgen Receptor ASXL1 ATRX B-Cell Gene Rearrangement BCL1 Translocation, t(11;14) BCL2 Translocation, t(14;18) BCR-ABL1 Non-Standard p230 BCR-ABL1 Standard p210, p190 BRCA1 Mutation & Del/Dup Analysis BRCA2 Mutation & Del/Dup Analysis BTK CALR CARD11 CBL CD79B CEBPA Chimerism/DNA Fingerprinting CSF3R CXCR4 DNMT3A T790M Germline Mutation Analysis viii Analysis EPCAM Mutation & Del/Dup Analysis ETV6 ETV6-RUNX1 Translocation, t(12;21) EZH2 FLT3 GNAS HOXB13 Genotyping HPV DNA Tissue Testing HRAS HSD3B1 Genotyping IDH1 & IDH2 IgH Clonality/MRD by NGS IgVH Inv(16), CBFB-MYH11 Translocation JAK2 Exon JAK2 V617F Exon 4 MET (c-met) MET Exon 14 Deletion Analysis MGMT Promoter Methylation Microsatellite Instability MLH1 Mutation & Del/Dup Analysis MLH1 Promoter Methylation MPL MYD88 MSH2 Mutation & Del/Dup Analysis MSH6 Mutation & Del/Dup Analysis NeoLAB T790M - NeoLAB FLT3 Mutation Analysis - NeoLAB IDH1 Mutation Analysis - NeoLAB IDH2 Mutation Analysis - NeoLAB inv(16), CBFB-MYH11 Translocation - NeoLAB (c-) Mutation Analysis - Liquid Biopsy NeoLAB Mutation Analysis - NeoLAB NPM1 Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB PML-RARA Translocation, t(15;17) - NeoLAB RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) - NOTCH1 NPM1 Exon 4 PML-RARA Translocation, t(15;17) PMS2 Mutation & Del/Dup Analysis PTPN11 PLC-Gamma-2 PMS2 Mutation & Del/Dup Analysis RHOA RUNX1 RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) SETBP1 SF3B1 SRSF2 STAT3 T-Cell Gamma Gene Rearrangement T-Cell Beta Gene Rearrangement TERT Promoter TET2 TP53 TPMT Genotyping U2AF1 UGT1A1 Genotyping VHL WT1 ZRSR2 6 NeoGenomics Laboratories
7 Panels and Profiles AML Reflex Panel BRCA1/2 Mutation & Del/Dup Analysis BTK Inhibitor Acquired Resistance Panel BTK Inhibitor Primary Susceptibility Panel Hereditary Cancer Comprehensive Panel Hereditary Cancer Susceptibility for Pediatrics Hereditary DNA Repair Panel for Prostate Cancer Inherited Bone Marrow Failure Panel Lynch Syndrome MPN Extended Reflex Panel MPN Standard Reflex Panel NeoARRAY SNP/Cytogenetic Profile NeoLAB AML Profile - NeoLAB BTK Inhibitor Acquired Resistance Panel - NeoLAB MDS/CMML Profile - NeoLAB Myeloid Disorders Profile - NeoLAB Prostate - Liquid to Biopsy NeoLAB Solid Tumor Monitor - NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile NeoTYPE AML Favorable-Risk Profile NeoTYPE AML Prognostic Profile NeoTYPE Brain Tumor Profile NeoTYPE Breast Tumor Profile NeoTYPE Cervical Tumor Profile NeoTYPE CLL Prognostic Profile NeoTYPE Colorectal Tumor Profile NeoTYPE Discovery Profile for Solid Tumors NeoTYPE Endometrial Tumor Profile NeoTYPE Esophageal Tumor Profile NeoTYPE Gastric Tumor Profile NeoTYPE GI Predictive Profile NeoTYPE GIST Profile NeoTYPE Head & Neck Tumor Profile NeoTYPE JMML Profile NeoTYPE Liposarcoma Fusion Profile NeoTYPE Liver/Biliary Tumor Profile NeoTYPE Lung Tumor Profile NeoTYPE Lymphoma Profile NeoTYPE MDS/CMML Profile NeoTYPE Melanoma Profile NeoTYPE MPN Profile NeoTYPE Myeloid Disorders Profile NeoTYPE Other Solid Tumor Profile NeoTYPE Ovarian Tumor Profile NeoTYPE Pancreas Tumor Profile NeoTYPE Precision Profile for Solid Tumors NeoTYPE Soft Tissue Tumor Profile NeoTYPE Thyroid Profile NGS ALK, NTRK, RET, ROS1 Fusion Profile NGS ALK, RET, ROS1 Fusion Profile NGS Comprehensive Sarcoma Fusion Profile NGS Ewing Sarcoma Fusion Profile NGS Non-Ewing Sarcoma Fusion Profile NGS Pediatric Sarcoma Fusion Profile NGS Rhabdomyosarcoma Fusion Profile NGS Thyroid Fusion Profile RAS/RAF Panel Tumor Mutation Burden Universal Fusion/Expression Profile Specimen and Ordering Information Specimen Requirements NeoGenomics molecular testing is routinely performed on blood, bone marrow aspirate, fixed cytogenetic pellets, fresh tissue, and formalin-fixed paraffin-embedded tissue of all types. Acceptable specimen types vary by test, so please see our website for requirements for the test of interest. Please inquire if you have an alternative specimen type as we can often accommodate these. Ordering Tests in panels or profiles may be ordered separately or in custom combinations. The most commonlyordered tests are shown, but for many diseases, more testing that encompasses emerging research and clinical trial opportunities is available. For an extended list of tests correlated with each tumor, please search by disease state on the NeoGenomics website. NeoGenomics Laboratories 7
8 NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories. Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information Commonwealth Dr., Suite 9 Fort Myers, FL Phone: / Fax: neogenomics.com 2018 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners. Rev
Out-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationPediatric Oncology & Pathology Services
Pediatric Oncology & Pathology Services Anatomic Pathology Flow Cytometry Cytogenetics Pharma Services Diagnostic, Prognostic, Predictive, and Predisposition Testing Pediatric Oncology & Pathology Services
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationmolecular oncology services
Molecular Oncology molecular oncology services ATIENTS.ANSWERS.RESULTS. www.aruplab.com/oncology MARCH 2018 Information in this brochure is current as of March 2018. All content is subject to change. lease
More informationTime Matters. Results Count! Company Overview Presentation. August Improving Patient Care through exceptional cancer genetic testing services!
Time Matters. Results Count! Company Overview Presentation August 2014 Improving Patient Care through exceptional cancer genetic testing services! Forward-looking Statements This presentation contains
More informationIllumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More informationNext Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
More informationPatricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope
Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationPrior Authorization Required: Additional Information:
Genetic Testing for Somatic Tumor Markers MP9486 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below No A first-degree relative is defined as an individual
More informationWest Midlands Regional Genetics Laboratory
West Midlands Regional Genetics Laboratory Haemato-oncology service update letter October 2017 Dear colleagues, We are writing to outline the latest developments to our service, aiming to support the management
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More informationCost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
More informationThe Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare
The Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare Jessica Wang-Rodriguez, MD Chief, VISN22 Consolidated Pathology and Laboratory Medicine Services
More informationADRL Advanced Diagnostics Research Laboratory
ADRL Advanced Diagnostics Research Laboratory John DeCoteau, MD FRCP Department of Pathology, Division of Hematopathology University of Saskatchewan Saskatchewan Cancer Agency ADRL Project Objectives New
More informationYour single-source laboratory solution. FISH Probe Library
Your single-source laboratory solution. FISH Probe Library Alphabetical List by Probe with Clinical Indication Probe Clinical Indication 1p36 (TP73)/19q13 (GLTSCR) 1q21 (CKS1B) 5q (CSF1R/RPS14) 7q (MDFIC)
More informationIntroduction of an NGS gene panel into the Haemato-Oncology MPN service
Introduction of an NGS gene panel into the Haemato-Oncology MPN service Dr. Anna Skowronska, Dr Jane Bryon, Dr Samuel Clokie, Dr Yvonne Wallis and Professor Mike Griffiths West Midlands Regional Genetics
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationInitial Diagnostic Workup of Acute Leukemia
Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationLaboratory Service Report
Client C7028846-DLP Rochester Rochester, N 55901 Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-zwselwql7p.ashx Indication for Test DS CR Pathogenic
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationEnhancing Assessment of Myeloid Disorders in the Era of Precision Medicine
Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center Objectives
More informationGenetic Testing for Somatic Tumor Markers
Genetic Testing for Somatic Tumor Markers MP9486 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Genetic testing is covered for a
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationLaboratory Service Report
Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-ih2xuglwpq.ashx Indication for Test DS CR Pathogenic utations Detected CR 1. JAK2: c.1849g>t;p.val617phe
More informationPrecision Medicine and Molecular Testing.
Precision Medicine and Molecular Testing. David A. Sallman, MD Assistant Member Department of Malignant Hematology Moffitt Cancer Center david.sallman@moffitt.org Disclosures Research funding for Celgene
More informationClick to edit Master /tle style
Click to edit Master /tle style Tel: (314) 747-7337 Toll Free: (866) 450-7697 Fax: (314) 747-7336 Email: gps@wustl.edu Website: gps.wustl.edu GENETIC TESTING IN CANCER Ka/nka Vigh-Conrad, PhD Genomics
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
More informationSelect analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie
Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:
More informationOverview. Methods 9/11/2017. Next Generation Sequencing and Precision Medicine in Hematological Malignancies. Genotyping in hematology
Overview Next Generation Sequencing and Precision Medicine in Hematological Malignancies Sharathkumar Bhagavathi, MD University of Iowa Carver College of Medicine NGS as a genotyping platform in hematopathology
More informationDiagnostic Molecular Pathology of Myeloid Neoplasms
Diagnostic Molecular Pathology of Myeloid Neoplasms Beirut, Lebanon Tuesday November 29, 2011: Pre-congress workshop Adam Bagg University of Pennsylvania Philadelphia, USA Myeloid neoplasms Myeloproliferative
More informationClinical Grade Biomarkers in the Genomic Era Observations & Challenges
Clinical Grade Biomarkers in the Genomic Era Observations & Challenges IOM Committee on Policy Issues in the Clinical Development & Use of Biomarkers for Molecularly Targeted Therapies March 31-April 1,
More informationMOLECULAR SERVICES. mlabs.umich.edu
MOLECULAR SERVICES mlabs.umich.edu 800.862.7284 PICTURED ON LEFT IS MARWAN TAYEH, PH.D, CLINICAL ASSISTANT PROFESSOR, PEDIATRICS - GENETICS, ON RIGHT IS TODD ACKLEY, LABORATORY MANAGER MLabs is a full-service
More informationUpdate on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester
Update on the WHO Classification of Acute Myeloid Leukemia Kaaren K. Reichard, MD Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Objectives Present a practical
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationEXT ADDRESS CITY LAST NAME ID NUMBER PT. ADDRESS CITY INSURANCE PROVIDER. 0 Other. 0 IGH/B-cell cionaliry (PCR)
THE UNIVERSITY OF TEXAS *Required Fields PHYSICIAN! FACILITY/ CLIENT INFORMATION MDAndersonefief &ter MaltgararEettcy 'REQUESTING PHYSICIAN Division of Pathology! Laboratory Medicine Services Test Requisition
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Haematopathology and Oncology Diagnostic Services (HODS) Addenbrookes Hospital Hills Road Cambridge CB2 0QQ Contact: Brian Warner Tel: +44
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More informationCurrent Techniques in Molecular Biology Friedel Nollet, Ph.D.
Current Techniques in Molecular Biology Friedel Nollet, Ph.D. Molecular Biology and Cytometry course May 16-17, 2013 Mol, SCK-CEN, Belgium Sanger DNA sequencing Kary Mullis received a Nobel Prize in chemistry
More informationMolecular Diagnostics Centre
Directorate of Central Manchester Haematology Service Molecular Diagnostics Centre Haemato-Oncology User Guide 2014 Page 1 of 13 Directorate of CONTENTS About Us 3 Contact Details 3 Location 3 Postal Address
More informationMatthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory
Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationDisclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.
RC1 Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations RC2 Disclosure: Nothing to disclose Henry Moon Lecture: UCSF Annual Conference Kathryn Foucar, MD kfoucar@salud.unm.edu May
More informationMolecular Diagnostics of Myeloid and Lymphoid Neoplasms
Molecular Diagnostics of Myeloid and Lymphoid Neoplasms Molecular Pathology: Principles in Clinical Practice - 2012 John Greg Howe Ph.D. Department of Laboratory Medicine Yale University School of Medicine
More informationWe are in an era that promises a rational. treatment of cancer patients. Levy et al. Genome Research 22:2201, 2012 Vanderbilt university
Enhancing Assessment of Leukemia with Next Generation Sequencing Michelle Afkhami, M.D. Medical Director, Clinical i l Molecular l Laboratory City of Hope National Medical Center How the Expert Treat Hematologic
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationSchool of Pathology and Laboratory Medicine: Current and New Research Interests
School of Pathology and Laboratory Medicine: Current and New Research Interests W/Professor Wendy Erber Current Research Interests Viral immunology and immunogenetics Bone pathology and cell signalling
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationAddressing the challenges of genomic characterization of hematologic malignancies using microarrays
Addressing the challenges of genomic characterization of hematologic malignancies using microarrays Sarah South, PhD, FACMG Medical Director, ARUP Laboratories Department of Pediatrics and Pathology University
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationShould Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!
Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!! Lindsay Anne Magura Rein, MD Division of Hematologic Malignancies and Cellular Therapy/BMT A Little Bit of History.. 1665 Advanced
More informationHEMATOPATHOLOGY SERVICES
HEMATOPATHOLOGY SERVICES Know what your patient s future holds, NOW. Driven by patient care, GoPath Laboratories has set a new standard for hematologic cancer testing. thick, 2 slides per probe minimum
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationBeyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure
Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationManagement of Myelodysplastic Syndromes
Management of Myelodysplastic Syndromes Peter L. Greenberg, MD Stanford Cancer Institute Myelodysplastic Syndromes: Clinical & Molecular Advances for Disease Classification and Prognostication MDSs: A
More informationObjectives and Financial Disclosure
Enhancing Assessment of Leukemia and Lymphoma with Next Generation Sequencing Michelle Afkhami, M.D. Medical Director, Clinical Molecular Laboratory Assistant Professor, Department of Pathology City of
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationCase #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed
Case #1 65 yo man with no prior history presented with leukocytosis and circulating blasts: WBC 187.4K/uL ; Hgb 10.0gm/dL; Platelet 68K/uL Neutrophil % 25.0% Lymphocyte % 38.0% Monocyte % 12.0% Metamyelocyte
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationGenetic Testing Oncology
Genetic Testing Oncology Policy Number: Original Effective Date: MM.02.010 05/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2014 Section: Medicine Place(s) of Service:
More informationAcute Myeloid Leukemia with RUNX1 and Several Co-mutations
Case SH2017-0281 Acute Myeloid Leukemia with RUNX1 and Several Co-mutations James Bauer, MD, PhD David Yang, MD Erik Ranheim, MD, PhD Catherine Leith, MB, Bchir Clinical History Chief Complaint: 72 year
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationSession 4: Summary and Conclusions
Session 4: Summary and Conclusions Total cases in Session 4 Myeloproliferative neoplasms 16 cases Oral #300 (CEL, NOS) Mastocytosis 2 cases Oral #156 (SM-AHN) Myeloid/lymphoid neoplasms with eosinophilia
More informationMolecular Genetic Testing for the Diagnosis of Haematological Malignancies
Molecular Genetic Testing for the Diagnosis of Haematological Malignancies Dr Anthony Bench Haemto-Oncology Diagnostic Service Cambrıdge Unıversıty Hospitals NHS Foundatıon Trust Cambridge UK Molecular
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationGENETICS OF HEMATOLOGICAL MALIGNANCIES
de DUVE INSTITUTE GENETICS OF HEMATOLOGICAL MALIGNANCIES INTERUNIVERSITY CERTIFICATE IN HUMAN GENETICS Université catholique de Louvain Brussels,19/02/2016 Professor Hélène Antoine-Poirel, MD, PhD Center
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationLynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
More informationMolecular profiling in confirming the diagnosis of early myelodysplastic syndrome
Molecular profiling of early MDS Hematopathology - March 2016 Article Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Maya Thangavelu 1,*, Ryan Olson 2, Li Li 2, Wanlong
More informationCleveland Clinic Laboratories. Anatomic Pathology
Cleveland Clinic Laboratories Anatomic Pathology OUR MISSION Cleveland Clinic Laboratories contributes to excellent patient care by providing high-quality, comprehensive laboratory testing and patient-focused
More informationPublished Ahead of Print on April 14, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation.
Published Ahead of Print on April 14, 2016, as doi:10.3324/haematol.2016.143214. Copyright 2016 Ferrata Storti Foundation. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse
More informationMEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17
MEDICAL POLICY SUBJECT: MOLECULAR PANEL TESTING OF PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationCLINICAL UTILITY OF INTEGRATED GENOMIC PROFILING IN PEDIATRIC LEUKEMIA
CLINICAL UTILITY OF INTEGRATED GENOMIC PROFILING IN PEDIATRIC LEUKEMIA FUMIN LIN, Ph.D. LINF1@EMAIL.CHOP.EDU CANCER GENOMIC DIAGNOSTIC LABORATORY DIVISION OF GENOMIC DIAGNOSTICS 1 PEDIATRIC LEUKEMIA Common
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationEnhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine
Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center How the
More informationOxford BRC Haemato-Molecular Diagnostic Service
Short User Guide Oxford BRC Haemato-Molecular Diagnostic Service The Oxford University Hospitals NHS trust s department of Haematology provides a comprehensive molecular diagnostic service for a range
More informationNext generation sequencing analysis - A UK perspective. Nicholas Lea
Next generation sequencing analysis - A UK perspective Nicholas Lea King s HMDC LMH is part of an integrated pathology service at King s Haematological Malignancy Diagnostic Centre (HMDC) HMDC serves population
More informationDate of Birth Gender Ethnicity/Family History Male Female Unknown. (Institutional Billing only. We DO NOT bill patients directly.)
PATIENT INFORMATION Last Name First M.I. CLINICAL LABORATORY Date of Birth Gender Ethnicity/Family History Male Female Unknown Molecular Diagnotics Patient or Sample ID# Institutional Account # (415) 514-8488
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationTargeted NGS in oncology and hemato-oncology using in-house designed gene panels. Joni Van der Meulen Molecular Diagnostics UZ Ghent (MDG) 24/03/2017
Targeted NGS in oncology and hemato-oncology using in-house designed gene panels Joni Van der Meulen Molecular Diagnostics UZ Ghent (MDG) 24/03/2017 MDG = Molecular Diagnostics UZ Ghent Center for Medical
More information